Mathur Radhika, Alver Burak H, San Roman Adrianna K, Wilson Boris G, Wang Xiaofeng, Agoston Agoston T, Park Peter J, Shivdasani Ramesh A, Roberts Charles W M
Program in Biological and Biomedical Sciences, Harvard Medical School, Boston, Massachusetts, USA.
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Nat Genet. 2017 Feb;49(2):296-302. doi: 10.1038/ng.3744. Epub 2016 Dec 12.
Genes encoding subunits of SWI/SNF (BAF) chromatin-remodeling complexes are collectively mutated in ∼20% of all human cancers. Although ARID1A is the most frequent target of mutations, the mechanism by which its inactivation promotes tumorigenesis is unclear. Here we demonstrate that Arid1a functions as a tumor suppressor in the mouse colon, but not the small intestine, and that invasive ARID1A-deficient adenocarcinomas resemble human colorectal cancer (CRC). These tumors lack deregulation of APC/β-catenin signaling components, which are crucial gatekeepers in common forms of intestinal cancer. We find that ARID1A normally targets SWI/SNF complexes to enhancers, where they function in coordination with transcription factors to facilitate gene activation. ARID1B preserves SWI/SNF function in ARID1A-deficient cells, but defects in SWI/SNF targeting and control of enhancer activity cause extensive dysregulation of gene expression. These findings represent an advance in colon cancer modeling and implicate enhancer-mediated gene regulation as a principal tumor-suppressor function of ARID1A.
编码SWI/SNF(BAF)染色质重塑复合物亚基的基因在所有人类癌症中约20%存在共同突变。尽管ARID1A是最常见的突变靶点,但其失活促进肿瘤发生的机制尚不清楚。在这里,我们证明Arid1a在小鼠结肠而非小肠中发挥肿瘤抑制作用,并且侵袭性ARID1A缺陷型腺癌类似于人类结直肠癌(CRC)。这些肿瘤不存在APC/β-连环蛋白信号通路成分的失调,而这些成分是常见形式的肠道癌症中的关键守门人。我们发现ARID1A通常将SWI/SNF复合物靶向增强子,在那里它们与转录因子协同作用以促进基因激活。ARID1B在ARID1A缺陷细胞中保留SWI/SNF功能,但SWI/SNF靶向和增强子活性控制的缺陷导致基因表达广泛失调。这些发现代表了结肠癌建模的进展,并表明增强子介导的基因调控是ARID1A的主要肿瘤抑制功能。